The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Morningstar brands and products Company Portfolio ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...